Form 4: Alector CEO Arnon Rosenthal Sells Shares for Tax Coverage
Statement of Changes in Beneficial Ownership
Alector CEO Arnon Rosenthal sold 87,216 shares of common stock to satisfy tax obligations related to RSU vesting.
Summary
- CEO Arnon Rosenthal sold 87,216 shares of Alector, Inc. (ALEC) common stock on June 2, 2026.
- The shares were sold at a weighted average price of $1.9743 per share, with individual transaction prices ranging from $1.92 to $2.08.
- The sale was executed to cover tax withholding obligations resulting from the vesting of restricted stock units (RSUs).
- Following the transaction, the CEO maintains direct beneficial ownership of 2,367,206 shares, in addition to indirect holdings through various family trusts.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the sale was purely administrative to cover tax obligations rather than a discretionary divestment.
Positives
- The sale was non-discretionary, specifically executed to satisfy tax obligations associated with equity compensation vesting.
Negatives
- The transaction represents a reduction in the CEO's direct equity stake in the company.
Risks
- The company remains subject to market volatility affecting its stock price, which currently trades near the $2.00 level.
Future Outlook
The filing does not provide forward-looking business guidance, as it is a mandatory disclosure of insider transaction activity.
Industry Context
StockSavvy.ai notes that tax-related sell-to-cover transactions are standard practice for executives in the biotechnology sector and generally do not signal a change in management's outlook on the company's long-term prospects.
Comparison to Industry Standards
- The transaction aligns with standard corporate governance practices where executives liquidate a portion of vested equity to meet tax liabilities.
- The scale of the sale is consistent with typical executive compensation structures in mid-cap biotech firms.
Stakeholder Impact
- Minimal impact on shareholders as the sale was for tax compliance purposes.
Key Dates
| Date | Description |
|---|---|
| 06/02/2026 | Date of the reported stock sale transaction. |
| 06/03/2026 | Date the Form 4 filing was submitted to the SEC. |
Keywords
Alector, ALEC, Insider Trading, Form 4, Biotech, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.